Print

IAVI 002

A Double-Blind, Randomized, Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a Candidate HIV-1 clade A DNA Vaccine, p THr-HIV A, in Healthy, HIV-Uninfected Volunteers

Trial Details:

I Completed
Kenya AIDS Vaccine Initiative (KAVI), International AIDS Vaccine Initiative (IAVI) February 01, 2001
DNA.HIVA Gag A
DNA.HIVA DNA
Kenya 18
http://www.iavi.org